Visual Recovery with Iloprost Added to Corticosteroids in a Case of Giant Cell Arteritis. (17th February 2022)

• Record Type: Journal Article
• Authors: Sené, Thomas; Arej, Nicolas; Lecler, Augustin; Dupont, Chloé; Vasseur, Vivien; Mauget-Faÿsse, Martine; Vignal-Clermont, Catherine
• Is Part Of: Ocular immunology and inflammation. Volume 30:Number 2(2022)
• Page Start: 497
• Page End: 499
• Publication Date: 2022-02-17
• Subjects: Giant cell arteritis -- ocular complications -- iloprost -- corticosteroids -- anterior ischemic optic neuropathy; Eye -- Diseases -- Immunological aspects -- Periodicals; Eye -- Inflammation -- Periodicals; 617.7
• DOI: 10.1080/09273948.2020.1802489
• Languages: English
• ISSNs: 0927-3948

Abstract

ABSTRACT: Introduction: To date, corticosteroids remain the cornerstone treatment of ocular involvement of GCA, and no other treatment has proven to be effective in this setting. We herein report on a unique case of GCA with ocular involvement worsening despite high dose corticosteroids and recovering with intravenous iloprost. Case report: A 70-year-old man presented with acute vision loss in his left eye related to anterior ischemic optic neuropathy. The diagnosis of giant-cell arteritis was confirmed by a temporal artery biopsy. Despite intravenous pulse methylprednisolone for 3 days then oral prednisone at 60 mg/day, the patient developed from day 5 fluctuating vision loss in the right eye, related to ocular ischemia by occlusion of the ophthalmic artery, and responsive to hyperhydration. Iloprost, an analog of prostacyclin PGI2, was then administered intravenously for 5 days and resulted in a stable improvement in visual acuity in the right eye. Conclusion: This case highlights the potential role of vasodilatator agents in giant cell arteritis with ocular involvement.